Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients

ConclusionsOur study confirms bIgE as a reliable biomarker predicting response to omalizumab in CSU, while it does not support the usefulness of bD ‐dimer unlike previous findings. CSU duration before omalizumab and baseline UAS7 may be clinical markers of relapse risk.This article is protected by copyright. All rights reserved.

Source: Journal of the European Academy of Dermatology and Venereology - November 19, 2018 Category: Dermatology Authors: A. V. Marzano, G. Genovese, G. Casazza, M. T. Fierro, P. Dapavo, N. Crimi, S. Ferrucci, P. Pepe, S. Liberati, P. D. Pigatto, A. Offidani, E. Martina, G. Girolomoni, M. Rovaris, C. Foti, L. Stingeni, A. Cristaudo, G. W. Canonica, E. Netti Tags: Original Article Source Type: research